Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity

Detalhes bibliográficos
Autor(a) principal: Lemos,Fernanda O.
Data de Publicação: 2016
Outros Autores: Villalba,Maria Imaculada C., Tagliati,Carlos A., Cardoso,Valbert N., Salas,Carlos E., Lopes,Miriam T.P.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Farmacognosia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2016000100094
Resumo: Abstract Prior studies demonstrate that a proteinase fraction from Vasconcellea cundinamarcensis V.M. Badillo, Caricaceae, exhibits wound healing activity in gastric and cutaneous models and antitumoral/antimetastatic effects. Here, we present the toxicity, pharmacokinetics and biodistribution data for this proteinase fraction following a single dose into Swiss mice by i.v., s.c. or p.o. routes. The i.v. and s.c. toxicity assays demonstrate that proteinase fraction at ≤20 mg/kg is non-lethal after single injection, while parental administration (p.o.) of ≤300 mg/kg does not cause death. Based on p.o. acute toxicity dose using Organisation for Economic Cooperation and Development protocols, proteinase fraction ranks as Class IV “harmful” substance. Proteinase fraction shows high uptake determined as Kp (distribution tissue/blood) in organs linked to metabolism and excretion. Also, high bioavailability (≈100%) was observed by s.c. administration. The blood contents following i.v. dose fits into a pharmacokinetic bi-compartmental model, consisting of high removal constants – kel 0.22 h−1 and kd 2.32 h−1and a half-life – t½ = 3.13 h. The Ames test of proteinase fraction (0.01–1%) demonstrates absence of mutagenic activity. Likewise, genotoxic evaluation of proteinase fraction (5 or 10 mg/kg, i.p.) shows no influence in micronuclei frequency. In conclusion, the acute doses for proteinase fraction lack mutagenic and genotoxic activity, clearing the way for clinical assays.
id SBFGNOSIA-1_fd75b1be5b6187e56718d2b3e08416ad
oai_identifier_str oai:scielo:S0102-695X2016000100094
network_acronym_str SBFGNOSIA-1
network_name_str Revista Brasileira de Farmacognosia (Online)
repository_id_str
spelling Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activityCaricaceaeCysteine proteinasesBiodistributionPharmacokineticsToxicityAbstract Prior studies demonstrate that a proteinase fraction from Vasconcellea cundinamarcensis V.M. Badillo, Caricaceae, exhibits wound healing activity in gastric and cutaneous models and antitumoral/antimetastatic effects. Here, we present the toxicity, pharmacokinetics and biodistribution data for this proteinase fraction following a single dose into Swiss mice by i.v., s.c. or p.o. routes. The i.v. and s.c. toxicity assays demonstrate that proteinase fraction at ≤20 mg/kg is non-lethal after single injection, while parental administration (p.o.) of ≤300 mg/kg does not cause death. Based on p.o. acute toxicity dose using Organisation for Economic Cooperation and Development protocols, proteinase fraction ranks as Class IV “harmful” substance. Proteinase fraction shows high uptake determined as Kp (distribution tissue/blood) in organs linked to metabolism and excretion. Also, high bioavailability (≈100%) was observed by s.c. administration. The blood contents following i.v. dose fits into a pharmacokinetic bi-compartmental model, consisting of high removal constants – kel 0.22 h−1 and kd 2.32 h−1and a half-life – t½ = 3.13 h. The Ames test of proteinase fraction (0.01–1%) demonstrates absence of mutagenic activity. Likewise, genotoxic evaluation of proteinase fraction (5 or 10 mg/kg, i.p.) shows no influence in micronuclei frequency. In conclusion, the acute doses for proteinase fraction lack mutagenic and genotoxic activity, clearing the way for clinical assays.Sociedade Brasileira de Farmacognosia2016-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2016000100094Revista Brasileira de Farmacognosia v.26 n.1 2016reponame:Revista Brasileira de Farmacognosia (Online)instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)instacron:SBFGNOSIA10.1016/j.bjp.2015.09.008info:eu-repo/semantics/openAccessLemos,Fernanda O.Villalba,Maria Imaculada C.Tagliati,Carlos A.Cardoso,Valbert N.Salas,Carlos E.Lopes,Miriam T.P.eng2016-02-03T00:00:00Zoai:scielo:S0102-695X2016000100094Revistahttp://www.sbfgnosia.org.br/revista/https://old.scielo.br/oai/scielo-oai.phprbgnosia@ltf.ufpb.br1981-528X0102-695Xopendoar:2016-02-03T00:00Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)false
dc.title.none.fl_str_mv Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
title Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
spellingShingle Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
Lemos,Fernanda O.
Caricaceae
Cysteine proteinases
Biodistribution
Pharmacokinetics
Toxicity
title_short Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
title_full Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
title_fullStr Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
title_full_unstemmed Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
title_sort Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity
author Lemos,Fernanda O.
author_facet Lemos,Fernanda O.
Villalba,Maria Imaculada C.
Tagliati,Carlos A.
Cardoso,Valbert N.
Salas,Carlos E.
Lopes,Miriam T.P.
author_role author
author2 Villalba,Maria Imaculada C.
Tagliati,Carlos A.
Cardoso,Valbert N.
Salas,Carlos E.
Lopes,Miriam T.P.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Lemos,Fernanda O.
Villalba,Maria Imaculada C.
Tagliati,Carlos A.
Cardoso,Valbert N.
Salas,Carlos E.
Lopes,Miriam T.P.
dc.subject.por.fl_str_mv Caricaceae
Cysteine proteinases
Biodistribution
Pharmacokinetics
Toxicity
topic Caricaceae
Cysteine proteinases
Biodistribution
Pharmacokinetics
Toxicity
description Abstract Prior studies demonstrate that a proteinase fraction from Vasconcellea cundinamarcensis V.M. Badillo, Caricaceae, exhibits wound healing activity in gastric and cutaneous models and antitumoral/antimetastatic effects. Here, we present the toxicity, pharmacokinetics and biodistribution data for this proteinase fraction following a single dose into Swiss mice by i.v., s.c. or p.o. routes. The i.v. and s.c. toxicity assays demonstrate that proteinase fraction at ≤20 mg/kg is non-lethal after single injection, while parental administration (p.o.) of ≤300 mg/kg does not cause death. Based on p.o. acute toxicity dose using Organisation for Economic Cooperation and Development protocols, proteinase fraction ranks as Class IV “harmful” substance. Proteinase fraction shows high uptake determined as Kp (distribution tissue/blood) in organs linked to metabolism and excretion. Also, high bioavailability (≈100%) was observed by s.c. administration. The blood contents following i.v. dose fits into a pharmacokinetic bi-compartmental model, consisting of high removal constants – kel 0.22 h−1 and kd 2.32 h−1and a half-life – t½ = 3.13 h. The Ames test of proteinase fraction (0.01–1%) demonstrates absence of mutagenic activity. Likewise, genotoxic evaluation of proteinase fraction (5 or 10 mg/kg, i.p.) shows no influence in micronuclei frequency. In conclusion, the acute doses for proteinase fraction lack mutagenic and genotoxic activity, clearing the way for clinical assays.
publishDate 2016
dc.date.none.fl_str_mv 2016-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2016000100094
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2016000100094
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjp.2015.09.008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
dc.source.none.fl_str_mv Revista Brasileira de Farmacognosia v.26 n.1 2016
reponame:Revista Brasileira de Farmacognosia (Online)
instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron:SBFGNOSIA
instname_str Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron_str SBFGNOSIA
institution SBFGNOSIA
reponame_str Revista Brasileira de Farmacognosia (Online)
collection Revista Brasileira de Farmacognosia (Online)
repository.name.fl_str_mv Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)
repository.mail.fl_str_mv rbgnosia@ltf.ufpb.br
_version_ 1752122469691424768